Trinity Biotech plc (TRIB) Stock

Trinity Biotech plc specializes in the acquisition, development, manufacturing, and global distribution of medical diagnostic products catering to clinical laboratory and point-of-care (POC) markets across the Americas, Africa, Asia, and Europe. The company's extensive portfolio includes diagnostic tests and instrumentation designed for detecting a wide range of infectious diseases such as Lyme disease, syphilis, herpes, SARS-CoV-2, Epstein Barr virus, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella, and other viral pathogens. Trinity Biotech also offers in-vitro diagnostic tests for hemoglobin A1c, crucial for monitoring and diagnosing diabetes and identifying individuals at risk of developing the condition.

In addition to its diagnostic capabilities, Trinity Biotech excels in manufacturing products across various assay formats including immunofluorescence assay, enzyme-linked immunosorbent assay (ELISA), western blot, and line immunoassay. The company provides a comprehensive range of reagent products essential for diagnosing liver and kidney diseases, as well as haemolytic anaemia, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase. Furthermore, Trinity Biotech supplies raw materials to the life sciences industry and research institutes, enhancing its role in advancing healthcare through collaborative partnerships.

Founded in 1992 and headquartered in Bray, Ireland, Trinity Biotech serves a diverse customer base that includes public health authorities, non-governmental organizations, clinical and reference laboratories, facilitated by a robust direct sales force and a network of independent distributors and strategic partners. With a commitment to innovation and quality, Trinity Biotech continues to play a vital role in advancing diagnostic capabilities globally, addressing critical healthcare challenges with cutting-edge solutions.